INTRAVENOUS THEOPHYLLINE THERAPY: NOMOGRAM GUIDELINES.JUSKO WJ; KOUP JR; VANCE JW et al.1977; ANN. INTERN. MED.; U.S.A.; DA. 1977; VOL. 86; NO 4; PP. 400-404; BIBL. 10 REF.Article

TISSUE PERSISTENCE OF GENTAMICIN IN MAN.SCHENTAG JJ; JUSKO WJ; PLAUT ME et al.1977; J.A.M.A.; U.S.A.; DA. 1977; VOL. 238; NO 4; PP. 327-329; BIBL. 13 REF.Article

GENTAMICIN DISPOSITION AND TISSUE ACCUMULATION ON MULTIPLE DOSING.SCHENTAG JJ; JUSKO WJ; VANCE JW et al.1977; J. PHARMACOKINET. BIOPHARMACEUT.; G.B.; DA. 1977; VOL. 5; NO 6; PP. 559-577; BIBL. 18 REF.Article

FACTORS AFFECTING THEOPHYLLINE CLEARANCES: AGE, TOBACCO, MARIJUANA, CIRRHOSIS, CONGESTIVE HEART FAILURE, OBESITY, ORAL CONTRACEPTIVES, BENZODIAZEPINES, BARBITURATES, AND ETHANOLJUSKO WJ; GARDNER MJ; MANGIONE A et al.1979; J. PHARM. SCI.; USA; DA. 1979; VOL. 68; NO 11; PP. 1358-1366; BIBL. 78 REF.Article

SYSTEM FOR CLINICAL PHARMACOKINETIC MONITORING OF THEOPHYLLINE THERAPY.KOUP JR; SCHENTAG JJ; VANCE JW et al.1976; AMER. J. HOSP. PHARM.; U.S.A.; DA. 1976; VOL. 33; NO 9; PP. 949-956; BIBL. 22 REF.Article